Athira Pharma (NASDAQ:ATHA) Receives Market Outperform Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Athira Pharma (NASDAQ:ATHA) in a research note released on Thursday, Benzinga reports. JMP Securities currently has a $19.00 target price on the stock.

Athira Pharma Stock Performance

Shares of ATHA stock opened at $2.29 on Thursday. Athira Pharma has a 52-week low of $1.33 and a 52-week high of $4.30. The firm has a market capitalization of $87.78 million, a P/E ratio of -0.75 and a beta of 2.91. The stock has a 50 day moving average price of $2.33 and a 200 day moving average price of $2.69.

Athira Pharma (NASDAQ:ATHA) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.11. As a group, sell-side analysts forecast that Athira Pharma will post -2.79 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Private Advisor Group LLC purchased a new position in Athira Pharma during the 4th quarter worth $32,000. Mirador Capital Partners LP purchased a new position in Athira Pharma during the 1st quarter worth $57,000. Forefront Analytics LLC increased its holdings in Athira Pharma by 43.0% during the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock worth $72,000 after purchasing an additional 8,955 shares during the period. Clarius Group LLC increased its holdings in Athira Pharma by 35.8% during the 4th quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock worth $130,000 after purchasing an additional 14,124 shares during the period. Finally, Laird Norton Trust Company LLC increased its holdings in shares of Athira Pharma by 21.3% in the 3rd quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock valued at $361,000 after acquiring an additional 31,400 shares during the period. 57.12% of the stock is currently owned by hedge funds and other institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.